Cargando…
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
PURPOSE: The addition of cytotoxic chemotherapy to immune-checkpoint inhibitor (ICI) may enhance antitumor effects. We conducted an open-label randomized phase II/III study to evaluate nivolumab + docetaxel combination therapy in comparison with nivolumab monotherapy for previously treated ICI-naïve...
Autores principales: | Taniguchi, Yuri, Shimokawa, Tsuneo, Takiguchi, Yuichi, Misumi, Toshihiro, Nakamura, Yukiko, Kawashima, Yosuke, Furuya, Naoki, Shiraishi, Yoshimasa, Harada, Toshiyuki, Tanaka, Hisashi, Miura, Satoru, Uchiyama, Ayumi, Nakahara, Yoshiro, Tokito, Takaaki, Naoki, Katsuhiko, Bessho, Akihiro, Goto, Yasuhiro, Seike, Masahiro, Okamoto, Hiroaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561604/ https://www.ncbi.nlm.nih.gov/pubmed/35980349 http://dx.doi.org/10.1158/1078-0432.CCR-22-1687 |
Ejemplares similares
-
Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426
por: Ichikawa, Yasuko, et al.
Publicado: (2023) -
P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022) -
Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)
por: Akamatsu, Hiroaki, et al.
Publicado: (2022) -
IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA
por: Oba, Utako, et al.
Publicado: (2020) -
Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913
por: Nakahara, Yoshiro, et al.
Publicado: (2020)